Home > Healthcare > Analytical Instruments > Molecular Analysis > Nucleic Acid Amplification Testing Market

Nucleic Acid Amplification Testing Market Size

Report ID: GMI8506
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Nucleic Acid Amplification Testing Market Size

Nucleic Acid Amplification Testing Market size was valued at around USD 7.3 billion in 2023 and is estimated to reach over USD 18.8 billion by 2032. Nucleic acid amplification testing (NAAT) is a molecular technique used to amplify and detect specific sequences of nucleic acids, such as DNA or RNA, within a sample. NAAT is employed in various fields including medical diagnostics, microbiology, and genetic research.

To get key market trends

Download Free Sample

Infectious diseases continue to pose a significant threat to global public health. The increasing prevalence of diseases such as HIV/AIDS, tuberculosis, hepatitis, and sexually transmitted infections necessitates accurate and rapid diagnostic methods. For instance, according to World Health Organization (WHO), in 2022, tuberculosis caused 1.3 million deaths, including 167,000 co-infected with HIV, making it the second leading infectious cause of death worldwide, surpassing HIV/AIDS.

There were 10.6 million new TB cases, affecting 5.8 million men, 3.5 million women, and 1.3 million children, highlighting its global prevalence across all demographics. Therefore, NAAT offers high sensitivity and specificity in detecting various pathogens, making it a crucial tool in the diagnosis and management of infectious diseases.

Nucleic Acid Amplification Testing Market Report Attributes
Report Attribute	Details
Base Year:	2023
Nucleic Acid Amplification Testing Market Size in 2023:	USD 7.3 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	11.3%
2032 Value Projection:	USD 18.8 Billion
Historical Data for:	2018 - 2023
No. of Pages:	206
Tables, Charts & Figures:	340
Segments covered:	Product Type, Technology, Application, End-use, and Region
Growth Drivers:	Rising prevalence of infectious diseases globally Increasing adoption of personalized medicine Growing demand for point of care testing Rising R&D investments for developing novel biotechnological diagnostic techniques
Pitfalls & Challenges:	High cost of instruments and reagents Stringent regulatory scenario

Learn more about the key segments shaping this market

Download Free Sample

Point-of-care testing (POCT) which is estimated to reach USD 78.3 billion by 2023, with NAAT technologies allows for rapid, accurate infectious disease diagnostics even at the remote locations. With quick results and decentralized testing, POCT meets the demand for timely diagnosis, improving patient care and stimulating NAAT adoption across healthcare settings.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global nucleic acid amplification testing market was valued at around USD 7.3 billion in 2023 and is estimated to reach over USD 18.8 billion by 2032, driven by the increasing prevalence of diseases such as HIV/AIDS, tuberculosis, hepatitis, and sexually transmitted infections.

The infectious disease testing segment is estimated to account for USD 8.9 billion by 2032, favored by the global prevalence of infectious diseases and the emergence of new pathogens.

In 2023, North America held a significant market share of 40.8%, attributed to the proactive regulatory frameworks and robust reimbursement policies in the region.

Abbott Laboratories, Becton, Dickinson, and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann La Roche AG, Illumina, Inc., QIAGEN N.V., Seegene Inc., and Siemens Healthineers AG.